ERBB2 and neoplasm: HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR-T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that was designed to help the immune system including HER2 specific CAR-T cell reacted to the tumor.https://clinicaltrials.gov/